IPO Details
Bidding Dates
06 May 24 - 08 May 24
Price Range ₹
430 - 452
Total Equity
₹ 0.00 Cr
Lot Size
33
Exchange Status
BSE,NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
7.95×
Qualified Institutional Buyers
197.55×
Employees
6.48×
Retail Investors
7.95×
Total subscription Rate
69.91×
IPO Timeline
Offer start
06 May 2024
Offer end
08 May 2024
Allotment
09 May 2024
Refund initiation
10 May 2024
Demat transfer
10 May 2024
Listing
13 May 2024
Offer start
06 May 2024
Offer end
08 May 2024
Allotment
09 May 2024
Refund initiation
10 May 2024
Demat transfer
10 May 2024
Listing
13 May 2024
About Company
Founded in 1998, Indegene Limited specializes in providing digital services for the life sciences industry, offering assistance with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaint management, and sales/marketing support. Their comprehensive range of services includes Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, Enterprise Clinical Solutions, and consultancy services.
Year Founded
16-10-1998
Promotor Details
Manish Gupta
Project Details
- General corporate purposes and inorganic growth - 2301.2cr
- Funding the capital expenditure requirements of our Company and our Material - 1029.16cr
- Repayment/prepayment of indebtedness of one of our Subsidiaries, ILSL Holdings, Inc - 3913.35cr
Objectives
- Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings, Inc.
- Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc.
- andGeneral corporate purposes and inorganic growth.
Highlights
- Indegene Limited has a solid track record of providing digital services to the life sciences industry since its establishment in 1998.
- The company offers a comprehensive range of services, including assistance with drug development, clinical trials, regulatory submissions, pharmacovigilance, and sales/marketing support, catering to various needs of its clients.
- Indegene has demonstrated consistent financial growth, with an 11.3% year-on-year increase in consolidated net profit and a 14.5% increase in revenue from operations for the nine-month period ended December FY24.
- The company has reported significant growth in net profit, with a 63.4% increase for the year ended March FY23 compared to the previous year.
- Indegene Ltd's IPO benefits from a robust portfolio of innovative solutions spanning enterprise commercial, medical, clinical, omnichannel activation, and NEXT Technology Platforms, catering to diverse needs within the healthcare industry and offering potential for comprehensive market penetration.
Challenges
- Indegene Limited's business is heavily reliant on the life sciences industry, which may subject it to the risks associated with changes in regulations, market trends, and competition within the sector.
- The company's performance may be affected by market volatility, which could impact investor confidence and the trading price of its equity shares after the IPO.
- Indegene's geographic presence may be limited, potentially restricting its ability to capture market opportunities in regions where it has a smaller footprint.
- The company operates in a competitive market, facing competition from both established players and emerging startups offering similar digital services to the life sciences industry.
- Regulatory changes or compliance issues within the life sciences industry could pose challenges for Indegene's operations and future growth prospects, impacting investor sentiment towards the IPO.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2019 | 3,26,27,72,000.00 | 78,87,31,800.00 | 18,32,67,600.00 | 18,32,67,600.00 | 0.9429 |
| 2022 | 12,843.14 | 3.51 | 35,43,11,600.00 | 35,43,11,600.00 | 1.8173 |
| 2018 | 3,07,71,13,000.00 | 78,87,24,200.00 | 14,09,10,800.00 | 14,09,10,800.00 | 0.7142 |
| 2020 | 5,616.13 | 3.13 | 1,628.18 | 1,647.62 | 7.4509 |
| 2021 | 5,593.02 | 3.13 | 1,628.18 | 1,647.62 | 7.4509 |
